US FDA Makes Flexibility Look Routine In TB Drug Review, But Not Everyone Is Pleased

The most remarkable aspect of the positive advisory committee for pretomanid is how routine FDA’s flexibility in the face of unmet need is starting to feel – but there are some dissenting voices that merit attention.